Affordable Access

Pilot study of p62 DNA vaccine in dogs with mammary tumors.

Authors
  • Gabai, Vladimir
  • Venanzi, Franco M
  • Bagashova, Elena
  • Rud, Oksana
  • Mariotti, Francesca
  • Vullo, Cecilia
  • Catone, Giuseppe
  • Sherman, Michael Y
  • Concetti, Antonio
  • Chursov, Andrey
  • Latanova, Anastasia
  • Shcherbinina, Vita
  • Shifrin, Victor
  • Shneider, Alexander
Type
Published Article
Journal
Oncotarget
Publisher
"Impact Journals, LLC "
Publication Date
Dec 30, 2014
Volume
5
Issue
24
Pages
12803–12810
Identifiers
PMID: 25296974
Source
Medline
License
Unknown

Abstract

Our previous data demonstrated profound anti-tumor and anti-metastatic effects of p62 (sqstm1) DNA vaccine in rodents with various types of transplantable tumors. Testing anti-cancer medicine in dogs as an intermediary step of translational research program provides two major benefits. First, clinical data collected in target animals is required for FDA/USDA approval as a veterinary anti-cancer drug or vaccine. It is noteworthy that the veterinary community is in need of novel medicine for the prevention and treatment of canine and feline cancers. The second more important benefit of testing anti-cancer vaccines in dogs is that spontaneous tumors in dogs may provide invaluable information for human trials. Here, we evaluated the effect(s) of p62 DNA vaccine on mammary tumors of dogs. We found that p62 DNA vaccine administered i.m. decreased or stabilized growth of locally advanced lesions in absence of its overall toxic effects. The observed antitumor activity was associated with lymphocyte infiltration and tumor encapsulation via fibrotic reaction. This data justifies both human clinical trials and veterinary application of p62 DNA vaccine.

Report this publication

Statistics

Seen <100 times